Brief: Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For Anaphylm
02/02/2026 12:35
Feb 2 (Reuters) - Aquestive Therapeutics Inc AQST.O: AQUESTIVE THERAPEUTICS ANNOUNCES FDA ISSUANCE OF COMPLETE RESPONSE LETTER FOR ANAPHYLM™ AQUESTIVE THERAPEUTICS INC - DEFICIENCIES LIMITED TO PACKAGING AND ADMINISTRATION AQUESTIVE THERAPEUTICS INC - COMPANY EXPECTS TO RESUBMIT AS EARLY AS Q3 2026 AQUESTIVE THERAPEUTICS INC - PLANS TO SUBMIT IN CANADA AND EU BY END OF 2026 AQUESTIVE THERAPEUTICS INC: PLANS TO REQUEST RAPID REVIEW BY FDA AQUESTIVE THERAPEUTICS INC - COMPANY ANTICIPATES ENDING 2026 WITH SIGNIFICANT CASH Source text: ID:nGNX1FQjSM Further company coverage: AQST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million